Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US

Journal of Medical Economics

Volumn 15, Issue SUPPL. 2, 2012, Pages 6-13

  Samyshkin, Yevgeniy ^a   Guillermin, Anne Laure ^a   Best, Jennie H ^b   Brunell, Steven C ^b   Lloyd, Adam ^a  

^a AIMS Health   (United Kingdom)

^b AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Cost effectiveness; Cost utility; Costs; Exenatide; Insulin glargine; Modeling; Type 2 diabetes; United States

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN; SULFONYLUREA;

ACUTE HEART INFARCTION; ADULT; ANGINA PECTORIS; ARTICLE; BODY MASS; CATARACT; CEREBROVASCULAR ACCIDENT; COMPUTER SIMULATION; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE DURATION; DRUG COST; FEMALE; FOOT ULCER; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY FAILURE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PROTEINURIA; QUALITY ADJUSTED LIFE YEAR; RETINA MACULA EDEMA; RETINOPATHY; SENSITIVITY ANALYSIS; VISUAL IMPAIRMENT;

ADMINISTRATION, CUTANEOUS; COMPUTER SIMULATION; COST OF ILLNESS; COST SAVINGS; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; MONTE CARLO METHOD; PEPTIDES; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES; VENOMS;

EID: 84864661021     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.708691     Document Type: Article

References (35)

1. VanDeKoppel S, Choe HM, Sweet BV. Managed care perspective on three new agents for type 2 diabetes. J Manag Care Pharm 2008;14:363-80 (Pubitemid 351890851)
2. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59
3. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32:193-203
4. Yanovski SZ, Yanovski JA. Obesity prevalence in the United States-up, down, or sideways? N Engl J Med 2011;364:987-9
5. Freedman DS. Obesity-United States, 1988-2008. Morbidity and Mortality Weekly Report-Surveillance Summaries 60, 73-77. 2011. Centers for Disease Control and Prevention (CDC), Atlanta, 2011.
6. World Health Organization. Non-communicable Disease Country Profile-United States of America-Obesity, 2006. Geneva: World Health Organization (WHO), https://apps.who.int/infobase/CountryProfiles.aspx. Accessed June 20, 2012.
7. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375:2234-43
8. LANTUS-(insulin glargine [rDNA origin] injection) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC, 2007.
9. BYETTA-(exenatide) Injection [prescribing information]. San diego, CA: Amlyin Pharmaceuticals, Inc., 2011.
10. Deyoung MB, Macconell L, Sarin V, et al. Encapsulation of exenatide in Poly-(d, l-Lactide-Co-Glycolide) microspheres produced an investigational longacting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 2011;13:1145-54
11. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86
12. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;252:837-53
13. American Diabetes Association Concensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262-5.
14. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(1 Suppl):S5-26
15. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(1 Sup):S27-40 (Pubitemid 39349906)
16. Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523-34 (Pubitemid 44297431)
17. Woodroffe R, Yao GL, Meads C, et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess 2005;9:1-179, iii-iv
18. Wasserfallen JB, Halabi G, Saudan P, et al. Quality of life on chronic dialysis: comparison between haemodialysis and peritoneal dialysis. Nephrol Dial Transplant 2004;19:1594-9 (Pubitemid 38786756)
19. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583-637
20. Sharma S, Oliver-Fernandez A, Bakal J, et al. Utilities associated with diabetic retinopathy: results from a Canadian sample. Br J Opthamol 2003;87:259-61 (Pubitemid 36307893)
21. Redekop WK, Stolk EA, Kok E, et al. Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes Metab 2004;30:549-56 (Pubitemid 40070357)
22. Lloyd A, Nafees B, Gavriel S, et al. Health utility values associated with diabetic retinopathy. Diabet Med 2008;25:618-24 (Pubitemid 351590891)
23. Hopkins RB, Tarride JE, Bowen J, et al. Cost-effectiveness of reducing wait times for cataract surgery in Ontario. Can J Ophthalmol 2008;43:213-7 (Pubitemid 351518174)
24. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-9 (Pubitemid 34791321)
25. Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. BMJ 1995;311:1595-9 (Pubitemid 26002703)
26. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-30 (Pubitemid 40360759)
27. Bergenstal RM, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-9
28. Boye KS, Matza LS, Walter KN, et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ 2011;12:219-30
29. Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007;16:1251-65 (Pubitemid 47357727)
30. PriceRx Medispan Wholesale Acquisition Costs (WAC). 2010. http://www.medi-span.com/index.aspx. Accessed 1 January, 2010.
31. Riddle MC, Henry RR, Poon TH, et al. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev 2006;22:483-91 (Pubitemid 44774053)
32. O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003;25:1017-38
33. Pelletier EM, Smith PJ, Boye KS, et al. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research. Appl Health Econ Health Policy 2008;6:103-12
34. Consumer Price Index for Medical Care Services. US Department of Labor, Bureau of Labor Statistics, 2006. http://www.bls.gov/cpi. Accessed July 1, 2010.
35. Beaudet A, Palmer JL, Timlin L, et al. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. J Med Econ 2011;14:357-66